{"id":"W4309412600","doi":"10.1016/s1470-2045(22)00621-0","title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":false,"ca_institutions":"Zymeworks (Canada); Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Oncology; Internal medicine; Trastuzumab; Adverse effect; Bispecific antibody; Metastatic breast cancer; Response Evaluation Criteria in Solid Tumors; Clinical trial; Phases of clinical research; Cancer; Monoclonal antibody; Antibody; Breast cancer; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001270465,0.0002218475,0.0008464765,0.0001002468,0.0004484542,0.00002726483,0.0003087282,0.00004555865,0.0004227901],"category_scores_gemma":[0.0001912168,0.0001092943,0.00007494701,0.0004364941,0.0002744471,0.00006208597,0.0001434233,0.0002638969,0.000001852995],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008933092,"about_ca_system_score_gemma":0.001139106,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007162091,"about_ca_topic_score_gemma":0.001290012,"domain_scores_codex":[0.9976741,0.0004480293,0.0004820824,0.0004500082,0.0004742369,0.0004715314],"domain_scores_gemma":[0.9968846,0.0018723,0.000261278,0.0007549152,0.0001350049,0.00009190082],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1432615,0.0133732,0.002129911,0.0005763394,0.001202963,0.0002925741,0.02503808,0.002214229,0.149564,0.0001701153,0.003214162,0.6589629],"study_design_scores_gemma":[0.1681501,0.1598862,0.01503921,0.0003617587,0.0017185,0.0005825471,0.06411113,0.03160539,0.005417978,0.000181138,0.5523329,0.0006131993],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9795477,0.001504312,0.005485368,0.005449549,0.0003938964,0.007087209,0.0003258356,0.00005580044,0.0001503684],"genre_scores_gemma":[0.9913887,0.001432236,0.003190825,0.0004550992,0.0003441649,0.002433787,0.00007865323,0.00005136712,0.0006251877],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6583498,"threshold_uncertainty_score":0.4629255,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2538568129815828,"score_gpt":0.5097609920992456,"score_spread":0.2559041791176628,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}